DeNovo Ventures

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products aimed at treating corneal disorders, particularly conditions associated with corneal weakness. The company's primary offerings include its Corneal Remodeling platform, which features the KXL and Mosaic systems that utilize ultraviolet A light, along with a range of single-use riboflavin drug formulations. These products are designed to address corneal ectatic disorders and correct refractive conditions, specifically in the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers in the United States, and also through international medical device distributors. Additionally, Avedro is advancing the field of Thermo-biomechanics for therapeutic applications, with the Keraflex refractive correction procedure being a notable development, offering a non-invasive method for corneal flattening without tissue removal. Avedro is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products aimed at treating corneal disorders, particularly conditions associated with corneal weakness. The company's primary offerings include its Corneal Remodeling platform, which features the KXL and Mosaic systems that utilize ultraviolet A light, along with a range of single-use riboflavin drug formulations. These products are designed to address corneal ectatic disorders and correct refractive conditions, specifically in the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers in the United States, and also through international medical device distributors. Additionally, Avedro is advancing the field of Thermo-biomechanics for therapeutic applications, with the Keraflex refractive correction procedure being a notable development, offering a non-invasive method for corneal flattening without tissue removal. Avedro is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

CD Group, Inc. is a consulting and managed services company based in Peachtree Corners, Georgia, with additional offices in Denver and Houston. Founded in 1992, it specializes in JD Edwards and Oracle enterprise solutions, offering project-based and support services across various technology areas. These include enterprise resource planning (ERP), business intelligence, enterprise performance management, and customer relationship management. CD Group provides a range of products, such as JD Edwards EnterpriseOne for ERP, Oracle Business Intelligence solutions, and Equip Q, an enterprise dealer management solution. The company is recognized as an industry leader and an Oracle Platinum Partner, serving clients throughout North America and internationally. Its services also encompass business consulting, analytics, and support, aimed at enhancing the value and return on investment of clients’ technology solutions.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, specializing in the design and development of non-fusion motion preservation systems for degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical properties of natural intervertebral discs. The M6 products incorporate an artificial nucleus and annulus to mimic a natural disc's structure. Spinal Kinetics distributes its products through a network of partners across multiple countries, including Australia, Canada, and various European nations. As a subsidiary of Orthofix Medical Inc., Spinal Kinetics collaborates with spine surgeons to advance innovative treatment options in spinal health.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products aimed at treating corneal disorders, particularly conditions associated with corneal weakness. The company's primary offerings include its Corneal Remodeling platform, which features the KXL and Mosaic systems that utilize ultraviolet A light, along with a range of single-use riboflavin drug formulations. These products are designed to address corneal ectatic disorders and correct refractive conditions, specifically in the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers in the United States, and also through international medical device distributors. Additionally, Avedro is advancing the field of Thermo-biomechanics for therapeutic applications, with the Keraflex refractive correction procedure being a notable development, offering a non-invasive method for corneal flattening without tissue removal. Avedro is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

Astute Medical, Inc. is a life science tools company focused on enhancing the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers for novel diagnostic tests. Established in 2007 and based in San Diego, California, with an additional location in Paris, the company specializes in prognostic biomarker validation, addressing rapid diagnosis and risk assessment for acute conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck test into a numerical result. Astute Medical operates in both the United States and Europe and is a subsidiary of bioMérieux S.A.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.

iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

Simpirica Spine was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

Astute Medical, Inc. is a life science tools company focused on enhancing the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers for novel diagnostic tests. Established in 2007 and based in San Diego, California, with an additional location in Paris, the company specializes in prognostic biomarker validation, addressing rapid diagnosis and risk assessment for acute conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck test into a numerical result. Astute Medical operates in both the United States and Europe and is a subsidiary of bioMérieux S.A.

TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Spiracur Inc. is a privately held medical device company established in 2007 through the Stanford Biodesign Innovation Program. The company specializes in creating innovative wound healing technologies aimed at improving patient care and clinician efficiency. Its flagship product, the SNaP Wound Care System, addresses the limitations of traditional negative pressure wound therapies, which can be cumbersome for both patients and healthcare providers. Spiracur focuses on developing solutions that prioritize patient needs and enhance the overall wound care experience.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

Astute Medical, Inc. is a life science tools company focused on enhancing the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers for novel diagnostic tests. Established in 2007 and based in San Diego, California, with an additional location in Paris, the company specializes in prognostic biomarker validation, addressing rapid diagnosis and risk assessment for acute conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck test into a numerical result. Astute Medical operates in both the United States and Europe and is a subsidiary of bioMérieux S.A.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Articulinx Inc. specializes in the manufacture of minimally-invasive implants and devices designed for the treatment of hand osteoarthritis. The company's products cater to the orthopedic, extremities, and small joints markets in the United States. Founded in 2007, Articulinx is headquartered in Cupertino, California, and focuses on providing innovative solutions to enhance patient care in the field of orthopedic medicine.

Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, specializing in the design and development of non-fusion motion preservation systems for degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical properties of natural intervertebral discs. The M6 products incorporate an artificial nucleus and annulus to mimic a natural disc's structure. Spinal Kinetics distributes its products through a network of partners across multiple countries, including Australia, Canada, and various European nations. As a subsidiary of Orthofix Medical Inc., Spinal Kinetics collaborates with spine surgeons to advance innovative treatment options in spinal health.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

Spiracur Inc. is a privately held medical device company established in 2007 through the Stanford Biodesign Innovation Program. The company specializes in creating innovative wound healing technologies aimed at improving patient care and clinician efficiency. Its flagship product, the SNaP Wound Care System, addresses the limitations of traditional negative pressure wound therapies, which can be cumbersome for both patients and healthcare providers. Spiracur focuses on developing solutions that prioritize patient needs and enhance the overall wound care experience.

Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

SynergEyes, Inc., a technology and OD-led contact lens company, manufactures and sells contact lens and other lens for eye care professionals. It offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, and irregular cornea conditions. It sells its products through distributors in the United States and internationally. SynergEyes, Inc. was formerly known as Quarter Lambda Technologies, Inc. The company was founded in 2001 and is based in Carlsbad, California.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Astute Medical, Inc. is a life science tools company focused on enhancing the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers for novel diagnostic tests. Established in 2007 and based in San Diego, California, with an additional location in Paris, the company specializes in prognostic biomarker validation, addressing rapid diagnosis and risk assessment for acute conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck test into a numerical result. Astute Medical operates in both the United States and Europe and is a subsidiary of bioMérieux S.A.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products aimed at treating corneal disorders, particularly conditions associated with corneal weakness. The company's primary offerings include its Corneal Remodeling platform, which features the KXL and Mosaic systems that utilize ultraviolet A light, along with a range of single-use riboflavin drug formulations. These products are designed to address corneal ectatic disorders and correct refractive conditions, specifically in the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers in the United States, and also through international medical device distributors. Additionally, Avedro is advancing the field of Thermo-biomechanics for therapeutic applications, with the Keraflex refractive correction procedure being a notable development, offering a non-invasive method for corneal flattening without tissue removal. Avedro is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Benvenue Medical, Inc. specializes in the design, manufacturing, and marketing of minimally invasive expandable implant systems for treating spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. The company offers products such as the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, aimed at treating various types of pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system designed for use in minimally invasive, mini-open, or open surgical procedures. Established in 2004 and headquartered in Santa Clara, California, the company serves a diverse customer base in the United States, Canada, Belgium, France, and Germany.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Vitreoretinal Technologies, Inc., an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.

Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

SynergEyes, Inc., a technology and OD-led contact lens company, manufactures and sells contact lens and other lens for eye care professionals. It offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, and irregular cornea conditions. It sells its products through distributors in the United States and internationally. SynergEyes, Inc. was formerly known as Quarter Lambda Technologies, Inc. The company was founded in 2001 and is based in Carlsbad, California.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Cartilix develops and commercializes biomaterials to repair damaged tissues in articular joints and other applications. It focuses on a technology for cartilage filling in regenerative medicine. The company was founded in 2004 and is based in Foster City, California.

Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, specializing in the design and development of non-fusion motion preservation systems for degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical properties of natural intervertebral discs. The M6 products incorporate an artificial nucleus and annulus to mimic a natural disc's structure. Spinal Kinetics distributes its products through a network of partners across multiple countries, including Australia, Canada, and various European nations. As a subsidiary of Orthofix Medical Inc., Spinal Kinetics collaborates with spine surgeons to advance innovative treatment options in spinal health.

Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, specializing in the design and development of non-fusion motion preservation systems for degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical properties of natural intervertebral discs. The M6 products incorporate an artificial nucleus and annulus to mimic a natural disc's structure. Spinal Kinetics distributes its products through a network of partners across multiple countries, including Australia, Canada, and various European nations. As a subsidiary of Orthofix Medical Inc., Spinal Kinetics collaborates with spine surgeons to advance innovative treatment options in spinal health.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Bacchus Vascular, Inc. offers medical devices for the treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States. It provides the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California.

iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

MicroVention Terumo is a medical device company specializing in catheter-based and minimally-invasive technologies for treating cerebral aneurysms and other neurovascular conditions. Founded in 1997 and headquartered in Tustin, California, the company develops a range of products, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Its notable technologies include the HydroCoil Embolic System, which utilizes platinum micro-coil technology for endovascular embolization, and the MicroPlex Coil System, designed for various aneurysm morphologies. MicroVention Terumo distributes its products through a network of specialty distributors across North America, South America, Europe, Africa, the Middle East, and Asia Pacific. The company has been operating as a subsidiary of Terumo Corporation since 2006.